InsidersTradesSigma
Cardiff Oncology, Inc. Stock: price and directors' dealings · United States · SEC (Form 4)
Track the Cardiff Oncology, Inc. stock price and the full insider trade history of the company, a listed equity based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Cardiff Oncology, Inc. has logged 20 public disclosures. Market capitalisation: €65.2m. The latest transaction was filed on 16 July 2026 (Acquisition). Among the most active insiders: PACE GARY W. Every trade is openly available.
20
Insider Decl.
n/a
Thresholds
€3m
19 ops.
Buy Volume
n/a
n/a
Sell Volume
60Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 16 July 2026
Declarations20 total
34,364 shares@ US$1.4550.083% mcap100.0% of flowCommon StockSEC:0001193125-26-306072:0
Canonical exit: 12 Oct 2026 (T+90)
687,285 shares@ US$1.4551.65% mcap31.1% of flowCommon StockSEC:0001193125-26-306083:0
Canonical exit: 12 Oct 2026 (T+90)
30,000 sharesCommon StockSEC:0001184778-26-000009:0
Canonical exit: 16 Sept 2026 (T+90)
24,703 sharesCommon StockSEC:0001664708-26-000002:0
Canonical exit: 16 Sept 2026 (T+90)
275,000 shares@ US$2.4530.4% of flowCommon StockSEC:0000950170-25-100882:0
Canonical exit: 28 Oct 2025 (T+90)
2,564 shares@ US$3.838.3% of flowCommon StockSEC:0000950170-24-137938:0
Canonical exit: 16 Mar 2025 (T+90)
10,000 shares@ US$3.422474.8% of flowCommon StockSEC:0000950170-24-136725:0
Canonical exit: 12 Mar 2025 (T+90)
350,115 shares@ US$2.6056.7% of flowCommon StockSEC:0000950170-24-135767:0
Canonical exit: 11 Mar 2025 (T+90)
30,000 shares@ US$1.372.5% of flowCommon StockSEC:0001628280-23-042045:0
Canonical exit: 18 Mar 2024 (T+90)
22,950 shares@ US$0.981.4% of flowCommon StockSEC:0001628280-23-038955:0
Canonical exit: 8 Feb 2024 (T+90)
10,000 shares@ US$1.43100.0% of flowCommon StockSEC:0001628280-22-030946:0
Canonical exit: 23 Feb 2023 (T+90)
13,000 shares@ US$1.556421.8% of flowCommon StockSEC:0001628280-22-026245:0
Canonical exit: 15 Dec 2022 (T+90)
15,000 shares@ US$1.63525.1% of flowCommon StockSEC:0001628280-22-025265:0
Canonical exit: 18 Dec 2022 (T+90)
30,000 shares@ US$1.55741.7% of flowCommon StockSEC:0001628280-22-025099:0
Canonical exit: 15 Dec 2022 (T+90)
6,400 shares@ US$1.71525.2% of flowCommon StockSEC:0001628280-22-025101:0
Canonical exit: 14 Dec 2022 (T+90)
150,000 shares@ US$1.7116.8% of flowCommon StockSEC:0001628280-22-025100:0
Canonical exit: 14 Dec 2022 (T+90)
28,858 shares@ US$2.6074.9% of flowCommon StockSEC:0001628280-22-018607:0
30,000 shares@ US$6.756.1% of flowCommon StockSEC:0001628280-21-019057:0
Canonical exit: 20 Dec 2021 (T+90)
5,000 shares@ US$6.6233.3% of flowCommon StockSEC:0001628280-21-018433:0
Canonical exit: 9 Dec 2021 (T+90)
4,000 shares@ US$10.817864.2% of flowCommon StockSEC:0001628280-21-011230:0
Canonical exit: 17 Jun 2021 (T+90)
20 of 20 declarations
关于 Cardiff Oncology, Inc.
Cardiff Oncology, Inc.是一家在美国上市的临床阶段生物技术公司，在纳斯达克交易，股票代码为CRDF。公司总部位于美国加利福尼亚州圣迭戈，其公司历史可追溯至1999年，之后发展成为目前专注于肿瘤学的战略。对于国际投资者而言，Cardiff Oncology符合开发阶段美国生物技术公司的特征：估值主要由临床进展、监管里程碑和资本需求驱动，而非当前的商业收入。该公司的核心资产是onvansertib，一种口服、高选择性的PLK1（Polo样激酶1）抑制剂。PLK1是一个经过验证的肿瘤学靶点，Cardiff的策略是通过将onvansertib与现有疗法结合，增强难治性癌症的标准化治疗方案。这种方法旨在创造临床差异化，而无需全新的骨干治疗方案。主要的开发项目集中在RAS突变转移性结直肠癌（mCRC）的一线治疗，onvansertib正在与FOLFIRI/贝伐珠单抗或FOLFOX/贝伐珠单抗等标准方案联合评估。除了结直肠癌，该公司还描述了研究者发起的或探索性的转移性胰腺导管腺癌、小细胞肺癌、三阴性乳腺癌和慢性粒单核细胞白血病研究。在竞争方面，Cardiff在一个拥挤的肿瘤创新领域运营，该领域由拥有更多资本资源、更广泛产品线和更成熟商业基础设施的大型生物技术和制药公司主导。其竞争优势取决于PLK1抑制的生物学特性、onvansertib的口服特性以及在生物标志物定义的患者亚群中显示有意义疗效的能力。最近的进展集中在CRDF-004试验在RAS突变mCRC一线治疗中取得的积极2期数据，相关更新于2025年发布，进一步的业务更新于2026年1月和2026年5月发布。该公司还于2026年宣布了领导层变动，因为它正在向后期临床开发和关键公司里程碑过渡。Cardiff最近的披露表明，下一阶段的价值创造将取决于确认反应的持久性、将试验数据转化为注册策略以及管理临床阶段生物技术公司典型的融资需求。对于投资者而言，机会巨大，但单一资产平台公司固有的二元临床风险也同样巨大。
